Humana has agreed to sell “all or substantially all” of its minority interest in hospice and palliative care provider Gentiva to a group of investors in a deal valued at $900 million.
The transaction, announced June 10, closes out Humana’s exit from the end-of-life care business it began to shed in 2022.
Humana picked up Gentiva when it bought the remaining stake in Kindred at Home in 2021, saying at the time it would eventually sell the non-core hospice and personal care assets. In 2022, it sold a 60% majority interest in those operations to private equity firm Clayton, Dubilier & Rice. Those divisions were then restructured into the standalone company Gentiva.
Gentiva operates more than 430 locations across 35 states and is the largest end-of-life care provider in the U.S., according to Humana. The company described the purchaser only as a “consortium of investors” and did not disclose financial terms beyond the stake valuation. The deal is expected to close in the third quarter, pending regulatory approval.
The proceeds will go toward general corporate purposes with no major impact to 2026 earnings.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.